BioSpace News Archive

TransThera today announced that the randomized, controlled, global multicenter Phase 3 trial (FIRST-308) of tinengotinib versus physician’s choice to evaluate the efficacy and safety in subjects with FGFR-altered, chemotherapy- and FGFR Inhibitor-refractory/relapsed cholangiocarcinoma (CCA).

GenScript is excited to announce that Dr. David R. Liu, a prominent figure in the field of genome editing, has been appointed to the company’s scientific advisory board (SAB).

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased to announce the non-exclusive engagement of Oak Hill Asset Management Inc. (“OHAM”), an Exempt Market Dealer to provide capital markets advice related to the Company’s capital markets strategy.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) announced the publication of results from a Phase 1 double-masked study of KIO-101, a potent, non-steroidal anti-inflammatory agent. KIO-101 contains the same active molecule as KIO-104, which belongs to a family of potent anti-inflammatory agents

Thermo Fisher Scientific Inc. today announced the launch of a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP).

Asha Therapeutics (Asha), ( www.ashatherapeutics.com ), a life sciences company, is leveraging its revolutionary PRISM™ drug design technology to create novel medicines to restore normal biology and provide functional cures for many difficult to treat diseases with a high unmet medical need.

Structure Therapeutics Inc. today reported financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent corporate achievements.

Acumen Pharmaceuticals, Inc. today presented cerebrospinal fluid (CSF) biomarker data from the sabirnetug (ACU193) Phase 1 INTERCEPT-AD trial in an oral presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD) in Lisbon, Portugal, and online.

Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to share additional data from its diagnostic 64Cu-SAR-bisPSMA trial, COBRA.

Scientific Industries, Inc. announced the appointment of John Nicols to the Board of Directors of SI and Chairman of its wholly, owned subsidiary, Scientific Bioprocessing Inc., effective March 4, 2024.